Given the critical role of ferroptosis in intracranial hemorrhage, these results may reveal a novel SAA-BASED therapy for patients with ICH, and the promotion of NRF2 activation through the Akt /GSK-3β pathway may be developed as a promising treatment for ICH. The gene discussed is AKT1; the disease is intracranial hemorrhage.